Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis

Divyanshu Dubey, Christopher A. Cano, Olaf Stüve

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Purpose of review There has been a considerable increase in the number of disease-modifying therapies (DMTs) in recent years. It appears that the number of approved DMTs is going to continue to increase in the coming years. The growing number of DMTs has provided a challenge to the clinician to tailor their therapeutic recommendations based on patients' needs and preferences. To choose between these DMTs, knowledge of side-effect profiles is imperative. Recent findings Alemtuzumab, a humanized recombinant monoclonal antibody, was recently approved for the management of relapsing forms of multiple sclerosis. Its use seems to be limited by significant adverse effects and regular monitoring requirement. In 2014, the first case of progressive multifocal leukoencephalopathy (PML) was diagnosed in a patient with relapsing remitting multiple sclerosis who received extended dimethyl fumarate without any significant confounding factors. Among patients receiving fingolimod after previous natalizumab treatment, there have been 17 suspected cases of PML. There have also been three confirmed cases of PML in individuals who received fingolimod without previous natalizumab treatment. Summary In this review, we outline the potential adverse effects and recommended laboratory studies as part of the monitoring strategy following initiation of various DMTs.

Original languageEnglish (US)
Pages (from-to)278-285
Number of pages8
JournalCurrent opinion in neurology
Volume29
Issue number3
DOIs
StatePublished - Jun 1 2016
Externally publishedYes

Fingerprint

Multiple Sclerosis
Progressive Multifocal Leukoencephalopathy
Therapeutics
Antibodies, Monoclonal, Humanized
Relapsing-Remitting Multiple Sclerosis
Patient Preference

Keywords

  • adverse effects
  • disease-modifying therapy
  • drug monitoring
  • multiple sclerosis

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis. / Dubey, Divyanshu; Cano, Christopher A.; Stüve, Olaf.

In: Current opinion in neurology, Vol. 29, No. 3, 01.06.2016, p. 278-285.

Research output: Contribution to journalReview article

@article{9199e8fe9db54ac09dc9a98d6c0453a3,
title = "Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis",
abstract = "Purpose of review There has been a considerable increase in the number of disease-modifying therapies (DMTs) in recent years. It appears that the number of approved DMTs is going to continue to increase in the coming years. The growing number of DMTs has provided a challenge to the clinician to tailor their therapeutic recommendations based on patients' needs and preferences. To choose between these DMTs, knowledge of side-effect profiles is imperative. Recent findings Alemtuzumab, a humanized recombinant monoclonal antibody, was recently approved for the management of relapsing forms of multiple sclerosis. Its use seems to be limited by significant adverse effects and regular monitoring requirement. In 2014, the first case of progressive multifocal leukoencephalopathy (PML) was diagnosed in a patient with relapsing remitting multiple sclerosis who received extended dimethyl fumarate without any significant confounding factors. Among patients receiving fingolimod after previous natalizumab treatment, there have been 17 suspected cases of PML. There have also been three confirmed cases of PML in individuals who received fingolimod without previous natalizumab treatment. Summary In this review, we outline the potential adverse effects and recommended laboratory studies as part of the monitoring strategy following initiation of various DMTs.",
keywords = "adverse effects, disease-modifying therapy, drug monitoring, multiple sclerosis",
author = "Divyanshu Dubey and Cano, {Christopher A.} and Olaf St{\"u}ve",
year = "2016",
month = "6",
day = "1",
doi = "10.1097/WCO.0000000000000321",
language = "English (US)",
volume = "29",
pages = "278--285",
journal = "Current Opinion in Neurology",
issn = "1350-7540",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis

AU - Dubey, Divyanshu

AU - Cano, Christopher A.

AU - Stüve, Olaf

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Purpose of review There has been a considerable increase in the number of disease-modifying therapies (DMTs) in recent years. It appears that the number of approved DMTs is going to continue to increase in the coming years. The growing number of DMTs has provided a challenge to the clinician to tailor their therapeutic recommendations based on patients' needs and preferences. To choose between these DMTs, knowledge of side-effect profiles is imperative. Recent findings Alemtuzumab, a humanized recombinant monoclonal antibody, was recently approved for the management of relapsing forms of multiple sclerosis. Its use seems to be limited by significant adverse effects and regular monitoring requirement. In 2014, the first case of progressive multifocal leukoencephalopathy (PML) was diagnosed in a patient with relapsing remitting multiple sclerosis who received extended dimethyl fumarate without any significant confounding factors. Among patients receiving fingolimod after previous natalizumab treatment, there have been 17 suspected cases of PML. There have also been three confirmed cases of PML in individuals who received fingolimod without previous natalizumab treatment. Summary In this review, we outline the potential adverse effects and recommended laboratory studies as part of the monitoring strategy following initiation of various DMTs.

AB - Purpose of review There has been a considerable increase in the number of disease-modifying therapies (DMTs) in recent years. It appears that the number of approved DMTs is going to continue to increase in the coming years. The growing number of DMTs has provided a challenge to the clinician to tailor their therapeutic recommendations based on patients' needs and preferences. To choose between these DMTs, knowledge of side-effect profiles is imperative. Recent findings Alemtuzumab, a humanized recombinant monoclonal antibody, was recently approved for the management of relapsing forms of multiple sclerosis. Its use seems to be limited by significant adverse effects and regular monitoring requirement. In 2014, the first case of progressive multifocal leukoencephalopathy (PML) was diagnosed in a patient with relapsing remitting multiple sclerosis who received extended dimethyl fumarate without any significant confounding factors. Among patients receiving fingolimod after previous natalizumab treatment, there have been 17 suspected cases of PML. There have also been three confirmed cases of PML in individuals who received fingolimod without previous natalizumab treatment. Summary In this review, we outline the potential adverse effects and recommended laboratory studies as part of the monitoring strategy following initiation of various DMTs.

KW - adverse effects

KW - disease-modifying therapy

KW - drug monitoring

KW - multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84961894481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961894481&partnerID=8YFLogxK

U2 - 10.1097/WCO.0000000000000321

DO - 10.1097/WCO.0000000000000321

M3 - Review article

C2 - 27027553

AN - SCOPUS:84961894481

VL - 29

SP - 278

EP - 285

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

IS - 3

ER -